Michael Smedley NUCRYST Pharmaceuticals Corp. NCS-T PAST TOP PICK Oct 19, 2006

The Silcryst bandaging spin off from Westaim (WED-T). (They still hold about 75%). Have developed/patented a technology for reducing nanotechnology silver to its crystalline level for application in ointments. Getting great revenues. Highly speculative.

(A Top Pick Aug 24/06. Down 79.5%.) Their cream for treating acne did not get approved by the FDA, but did get approval 2 weeks ago. It might still be interesting. Sold his holdings.

Their acne treatment was not approved previously by the FDA, but suddenly was in July.. The approval isn’t doing a great deal for it.